Beta adrenergic receptor: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
VisualWikitext
(add content based on adrenergic receptor page)
Line 34: Line 34:
| journal = Psychosomatic Medicine    | volume = 74  | issue = 1  | page = 46-54| date    = 2012| pmid    = | pmc = PMC3256093 | url = https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/
| journal = Psychosomatic Medicine    | volume = 74  | issue = 1  | page = 46-54| date    = 2012| pmid    = | pmc = PMC3256093 | url = https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/
| doi    = 10.1097/PSY.0b013e31824152ed}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/ (Full text)]
| doi    = 10.1097/PSY.0b013e31824152ed}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256093/ (Full text)]
*2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome
*2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome<ref name="Loebel2016">{{Cite journal|last1  = Loebel            | first1 = M          | authorlink1 = Madlen Loebel | last2  = Grabowski        | first2 = P          | authorlink2 = Patricia Grabowski| last3  = Heidecke          | first3 = H        | authorlink3 = | last4  = Bauer            | first4 = S          | authorlink4 = | last5  = Hanitsch          | first5 = LG          | authorlink5 = | last6  = Wittke            | first6 = K          | authorlink6 = | last7  = Meisel            | first7 = C          | authorlink7 = | last8  = Reinke            | first8 = P          | authorlink8 = | last9  = Volk              | first9 = H          | authorlink9 = | last10  = Fluge            | first10 = Ø          | authorlink10 = Øystein Fluge| last11  = Mella            | first11 = O        | authorlink11 = Olav Mella| last12  = Scheibenbogen    | first12 = C          | authorlink12 = Carmen Scheibenbogen| title  = Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome| journal = Brain, behavior, and immunity    | volume = 52  | issue =    | page = 32-39| date    = 2016 | doi    = 10.1016/j.bbi.2015.09.013 | url = https://www.sciencedirect.com/science/article/pii/S0889159115300209 }}</ref> - [https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)]
<ref name="Loebel2016 ">{{Cite journal|last1  = Loebel            | first1 = M          | authorlink1 = Madlen Loebel | last2  = Grabowski        | first2 = P          | authorlink2 = Patricia Grabowski| last3  = Heidecke          | first3 = H        | authorlink3 = | last4  = Bauer            | first4 = S          | authorlink4 = | last5  = Hanitsch          | first5 = LG          | authorlink5 = | last6  = Wittke            | first6 = K          | authorlink6 = | last7  = Meisel            | first7 = C          | authorlink7 = | last8  = Reinke            | first8 = P          | authorlink8 = | last9  = Volk              | first9 = H          | authorlink9 = | last10  = Fluge            | first10 = Ø          | authorlink10 = Øystein Fluge| last11  = Mella            | first11 = O        | authorlink11 = Olav Mella| last12  = Scheibenbogen    | first12 = C          | authorlink12 = Carmen Scheibenbogen| title  = Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome| journal = Brain, behavior, and immunity    | volume = 52  | issue =    | page = 32-39| date    = 2016 | doi    = 10.1016/j.bbi.2015.09.013 | url = https://www.sciencedirect.com/science/article/pii/S0889159115300209
*2018, [[Immunoadsorption]] to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref name="Immunoadsorption2018">{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Loebel|first2=Madlen|author-link2=Madlen Löbel|last3=Freitag|first3=Helma|author-link3=Helma Freitag|last4=Krueger|first4=Anne|last5=Bauer|first5=Sandra|author-link5=Sandra Bauer|last6=Antelmann|first6=Michaela|last7=Doehner|first7=Wolfram|last8=Scherbakov|first8=Nadja|last9=Heidecke|first9=Harald|last10=Reinke|first10=Petra|last11=Volk|first11=Hans-Dieter|last12=Grabowski|first12=Patricia|author-link12=Patricia Grabowski|date=2018|title=Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME|url=http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672|journal=PLoS ONE|volume=13|issue=3|pages=e0193672|doi=10.1371/journal.pone.0193672|via=}}</ref> - [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)]
}}</ref> -[https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)]
*2018, [[Immunoadsorption]] to remove ß2 adrenergic receptor antibodies in [[Chronic Fatigue Syndrome]] [[ME/CFS|CFS/ME]]<ref name="Immunoadsorption2018">{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Loebel|first2=Madlen|author-link2=Madlen Löbel|last3=Freitag|first3=Helma|author-link3=Helma Freitag|last4=Krueger|first4=Anne|last5=Bauer|first5=Sandra|author-link5=Sandra Bauer|last6=Antelmann|first6=Michaela|last7=Doehner|first7=Wolfram|last8=Scherbakov|first8=Nadja|last9=Heidecke|first9=Harald|last10=Reinke|first10=Petra|last11=Volk|first11=Hans-Dieter|last12=Grabowski|first12=Patricia|author-link12=Patricia Grabowski|date=2018|title=Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME|url=http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672|journal=PLoS ONE|volume=13|issue=3|pages=e0193672|doi=10.1371/journal.pone.0193672|via=}}</ref> - [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)]
* 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts<ref name="Bynke2020">{{Cite journal|last=Bynke|first=Annie|author-link=|last2=Julin|first2=Per|author-link2=|last3=Gottfries|first3=Carl-Gerhard|author-link3=Carl-Gerhard Gottfries|last4=Heidecke|first4=Harald|author-link4=|last5=Scheibenbogen|first5=Carmen|author-link5=Carmen Scheibenbogen|last6=Bergquist|first6=Jonas|author-link6=Jonas Bergquist|date=2020-08-01|title=Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts|url=http://www.sciencedirect.com/science/article/pii/S2666354620300727|journal=Brain, Behavior, & Immunity - Health|language=en|volume=7|issue=|pages=100107|doi=10.1016/j.bbih.2020.100107|issn=2666-3546|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [http://www.sciencedirect.com/science/article/pii/S2666354620300727 (Full text)]
* 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts<ref name="Bynke2020">{{Cite journal|last=Bynke|first=Annie|author-link=|last2=Julin|first2=Per|author-link2=|last3=Gottfries|first3=Carl-Gerhard|author-link3=Carl-Gerhard Gottfries|last4=Heidecke|first4=Harald|author-link4=|last5=Scheibenbogen|first5=Carmen|author-link5=Carmen Scheibenbogen|last6=Bergquist|first6=Jonas|author-link6=Jonas Bergquist|date=2020-08-01|title=Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts|url=http://www.sciencedirect.com/science/article/pii/S2666354620300727|journal=Brain, Behavior, & Immunity - Health|language=en|volume=7|issue=|pages=100107|doi=10.1016/j.bbih.2020.100107|issn=2666-3546|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [http://www.sciencedirect.com/science/article/pii/S2666354620300727 (Full text)]
*2020, Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls<ref name="Cakiroglu2020">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/ (Full text)]
*2020, Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls<ref name="Cakiroglu2020">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/ (Full text)]
* 2021,


==News articles and blogs==
==News articles and blogs==

Revision as of 21:22, January 18, 2022

The adrenergic receptors (or adrenoceptors) are a class of guanine nucleotide regulatory binding protein receptors (G protein-coupled receptors) that are targets of the catecholamines, especially norepinephrine (noradrenaline) and epinephrine (adrenaline).[1]

Adrenergic receptors mediate the effects of norepinephrine, epinephrine, and many adrenergic prescription drugs.[2]

Types[edit | edit source]

Beta adrenergic or β adrenergic receptors are also known as β-ARs or β AdR, have a key role in cardiac regulation.[1]

The beta-adrenergic receptors are:

ME/CFS[edit | edit source]

In 2015, a relatively large German study found 29% of ME/CFS patients had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors, as well as ß2 adrenergic receptors.[3]

In 2020, a small Sweden study confirmed these results in two different patient cohorts, but did not find a relationship between adrenergic receptors and the severity of ME.[4] The study assessed patients with moderate ME who met the Canadian and international consensus criteria for ME, plus the Systemic Exertion Intolerance Disease criteria, and found that the majority of patients had raised blood plasma concentration of β1, β2, M3 and M4-receptor autoantibodies but cerebral spinal fluid levels were normal. Only 25% of healthy controls had raised autoantibody levels.[4] These findings supported the autoimmune hypothesis for a subset of patients.

Notable studies[edit | edit source]

  • 2012, Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls[5] (Full text)
  • 2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome[3] - (Full Text)
  • 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[6] - (Full Text)
  • 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts[4] - (Full text)
  • 2020, Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls[7] - (Full text)

News articles and blogs[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 Wachter, S. Blake; Gilbert, Edward M. (2012). "Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application". Cardiology. 122 (2): 104–112. doi:10.1159/000339271. ISSN 0008-6312. PMID 22759389.
  2. ↑ Bylund, D. B. (January 1, 2013). Lennarz, William J.; Lane, M. Daniel (eds.). Adrenergic Receptors. Waltham: Academic Press. pp. 57–60. ISBN 978-0-12-378631-9.
  3. ↑ 3.0 3.1 Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, K; Meisel, C; Reinke, P; Volk, H; Fluge, Ø; Mella, O; Scheibenbogen, C (2016). "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome". Brain, behavior, and immunity. 52: 32-39. doi:10.1016/j.bbi.2015.09.013.
  4. ↑ 4.0 4.1 4.2 Bynke, Annie; Julin, Per; Gottfries, Carl-Gerhard; Heidecke, Harald; Scheibenbogen, Carmen; Bergquist, Jonas (August 1, 2020). "Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts". Brain, Behavior, & Immunity - Health. 7: 100107. doi:10.1016/j.bbih.2020.100107. ISSN 2666-3546.
  5. ↑ White, AT; Light, AR; Hughen, RW; Vanhaitsma, TA; Light, KC (2012). "Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls". Psychosomatic Medicine. 74 (1): 46-54. doi:10.1097/PSY.0b013e31824152ed. PMC 3256093.
  6. ↑ Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald; Reinke, Petra; Volk, Hans-Dieter; Grabowski, Patricia (2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLoS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672.
  7. ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788641/

β β / Β. Greek letter beta (a symbol used in science), equivalent to "b".

β β / Β. Greek letter beta (a symbol used in science), equivalent to "b".

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

plasma The liquid part of blood, lymph, or milk after removing any suspended material. Most of the time, "plasma" simply refers to blood, after all the blood cells have been removed. If you also remove the clotting factors, then the plasma is referred to as "serum".

cerebral 1. of or relating to the brain or the intellect 2. of, relating to, affecting, or being the cerebrum.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

metabolite A chemical compound produced by, or involved in, metabolism. The term is often used to refer to the degradation products of drugs in the body.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

cholinergic Involving the neurotransmitter acetylcholine. Cholinergic side effects include diarrhea, blurred vision, decreased intraocular pressure, contricted pupil in the eyes, sweating, increased saliva and mucus on the lungs, bronchial constriction, increased gastrointestinal tone, decreased blood pressure, slow heart rate, and contraction of bladder detrusor muscle. muscle spasms/cramps, low blood pressure, slowed heart rate, nausea and vomiting, increased saliva and sweating, shortness of breath, and urinating more often.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

somatic symptom disorder A psychiatric term to describe an alleged condition whereby a person's thoughts somehow cause physical symptoms. The actual existence of such a condition is highly controversial, due to a lack of scientific evidence. It is related to other psychiatric terms, such as "psychosomatic", "neurasthenia", and "hysteria". Older terms include "somatization", "somatoform disorder", and "conversion disorder". Such terms refer to a scientifically-unsupported theory that claims that a wide range of physical symptoms can be created by the human mind, a theory which has been criticized as "mind over matter" parapsychology, a pseudoscience.

Retrieved from "https://me-pedia.org/w/index.php?title=Beta_adrenergic_receptor&oldid=96668"